![]() ![]() Proposals that address conditions or clinical indications where current preventative, diagnostic, or treatment options disproportionately fail to serve underrepresented populations are encouraged.Īll pre-proposals, full proposals, and deep dive discussions will be conducted on a confidential basis. This may be addressed by including team members or collaborators from groups that are traditionally underrepresented in the translational workforce or by considering population factors such as racial and ethnic groups, gender, and disabilities. The Seedling program is akin to a planning grant that will provide training and mentoring to help applicants refine the intended target product profile and regulatory and reimbursement strategies in order to strengthen subsequent applications to this or other translational funding programs.Īpplicants should consider avenues to support diversity, equity, inclusion, and accessibility in their proposals. A subset of the applicants who submit full proposals will be selected to participate in an interactive “deep dive” evaluation, which is the final stage of review prior to funding decisions.Īnother subset of the applicants who submit full proposals will be invited to participate in the companion Seedling program and be awarded up to $50,000 total cost. The full proposal form is equivalent to approximately ten pages. Pre-proposals are submitted through a simple online application form equivalent to approximately four pages.Ī subset of applicants will be invited to submit full proposals through the same online application system. The Blueprint MedTech Hubs and NIH encourage applications from women, underrepresented racial and ethnic groups, as well as individuals with disabilities.Īpplicants must submit pre-proposals, which will undergo review by CINTA, NTH, and NIH program staff. Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Principal Investigator(s) is (are) invited to work with their organization to develop and submit a proposal. Principal Investigators (PIs) from academic institutions, industry, and non-profit organizations are invited to apply. The mentors will work with awardees throughout the project to focus on business, regulatory, clinical, and technical factors necessary for commercialization. Awardees will also receive ongoing, specialized support from mentors experienced in commercializing medical devices. In addition to monetary support, resources necessary for translation will be available from third-party-providers ( BP MedTech Resources and Support Services). Or have secured or be ready to apply to other NIH or non-governmental funding sources.Īwards will rarely exceed $500,000 in direct costs per year for a period of up to 4 years. Blueprint Medtech: Small Business Translator (U44 – Clinical Trial Optional).Blueprint MedTech: Translator (UG3/UH3 – Clinical Trial Optional).By the conclusion of funding, it is anticipated that all projects will be ready for entry into the companion solicitations from NIH (which support first-in-human evaluations of safety and effectiveness): Human subjects research beyond usability studies or studies classified as IRB-exempt are unlikely to be supported through this funding. ![]() The objective of Hub support is to develop and de-risk these groundbreaking technologies to the point of first-in-human-testing. The Center for Innovative NeuroTech Advancement (CINTA) and NeuroTech Harbor (NTH) are the two NIH-funded Incubator Hubs that will provide funding and in-kind resources to innovator teams. Other resources listed on the Blueprint MedTech Website.Resources to plan and support concept development, team building, needs assessment, and other early translational activities.Assistance from Hubs and consultants (e.g., on design, regulatory, reimbursement, intellectual property, commercialization, and strategic partnership issues).This program will catalyze the translation of novel technologies from early-stage development to a prototype ready for first-in-human-testing and will provide: (a) non-dilutive funds to support medical device development activities, (b) ongoing, specialized support from experienced executive mentors and (c) additional resources and support services including, but not limited to: The NIH Blueprint MedTech: Incubator Hubs aim to address such challenges by accelerating the development of cutting-edge medical devices that will prevent, diagnose, and/or treat disorders involving the nervous system or consequences of such a disease or injury. Innovators developing groundbreaking medical device technologies face several challenges along the translational path from bench to bedside. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |